Position of the Transparency Council – Omvoh (mirikizumab)
At its meeting on 5 August 2024, the Transparency Council adopted position No. 81/2024 on the evaluation of the drug Omvoh (mirikizumab) under the drug program: “Treatment of patients with ulcerative colitis (UC) (ICD-10: K51)”
Publication of the position >>